RxDoctor Payments Data

Ashley Walker, DO

Family Medicine · Miami, OKNPI 1093155111

Payments from drug & device makers

$907in general payments, 2019–2025

Across 51 payments — averaging $17.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$499
  • AbbVie$176
  • Lilly USA, LLC$59
  • Dexcom, Inc.$45
  • Amgen$27
  • Axsome Therapeutics, Inc.$21
  • plus $79 from 5 others

What the payments were for

  • Food & beverage$907100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$907 in reported general payments places this provider in the 60th percentile of 1,730 family medicine providers in Oklahoma.

See all family medicine providers in Oklahoma

Medicare billing

Part B allowed, 2024
$1,092
Medicare patients
18
Services billed
130

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide185$213,325
EliquisApixaban92$73,629
MounjaroTirzepatide44$51,743
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$51,629
JardianceEmpagliflozin33$41,405
TrulicityDulaglutide27$26,074
XareltoRivaroxaban41$23,463
MyrbetriqMirabegron21$16,956
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog17$15,564
Aimovig AutoinjectorErenumab-Aooe11$8,309
Combivent RespimatIpratropium/Albuterol Sulfate14$7,816
SymbicortBudesonide/Formoterol Fumarate21$6,595
Gabapentin365$6,368
Breo ElliptaFluticasone/Vilanterol11$6,217
BelsomraSuvorexant14$6,044

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$499$213,325185 claims
Lilly USA, LLCMounjaro, Trulicity$59$77,81871 claims
PfizerEliquis$15$73,62992 claims
AstraZenecaSymbicort$19$6,59521 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,730 family medicine providers in Oklahoma.

Other family medicine in Miami

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →